Last updated: February 24, 2026
Case Overview
Horizon Medicines LLC filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc., docket number 2:20-cv-08188-SRC-CLW, in the District of New Jersey. The case centers on Horizon’s allegations that Teva's generic version infringes on its patented drug formulations.
Patent Claims and Technology
Horizon’s patent relates to a specific compression method for making multi-layered tablets with controlled-release properties. The patent number is US Patent No. 10,657,088, granted on May 19, 2020.
Key elements include:
- The use of a specific binder composition during tablet compression.
- A layered structure with controlled-release profiles.
- A manufacturing process that enhances drug stability and bioavailability.
Teva's accused product is a generic version of Horizon’s multi-layered controlled-release medication, [generic drug name].
Timeline and Procedural Posture
-
October 19, 2020: Complaint filed.
-
December 14, 2020: Teva files its answer, denying infringement and asserting invalidity claims based on anticipation and obviousness.
-
July 15, 2021: Horizon seeks a preliminary injunction; the motion is denied in August 2021.
-
February 10, 2022: Claim construction hearing.
-
May 17, 2022: Court issues Markman ruling, interpreting key claim terms as follows:
- "Binder composition" refers to a specific range of polymeric materials.
- "Layered tablet" requires a distinct physical separation between layers as defined in the patent specification.
- "Controlled-release" implies sustained release over a specified time, explicitly linked to the specific patent parameters.
-
June 21, 2022: Disclosure of invalidity and non-infringement defenses by Teva.
-
Status (as of March 2023): Case remains in discovery, with motions for summary judgment pending.
Legal Issues
Patent Validity
Teva challenges the '088 patent’s validity based on:
- Obviousness under 35 U.S.C. § 103, arguing prior art references render the patent claims obvious.
- Novelty issues under 35 U.S.C. § 102, citing earlier publications describing similar layered tablet structures.
Infringement
Horizon asserts that Teva’s generic product uses the patented binder composition and layer structure, infringing claim elements explicitly, as detailed in the patent’s claim construction.
Defenses
Teva’s defenses include:
- Patent invalidity due to prior art.
- Non-infringement, asserting differences in manufacturing processes.
- Inequitable conduct during patent prosecution.
Market and Business Impact
The ruling could influence the commercial landscape for controlled-release formulations. If Horizon prevails, market exclusivity could extend beyond the patent’s expiration, delaying generic entry. A finding of invalidity or non-infringement would facilitate generics, potentially reducing treatment costs.
Key Development Risks
- Invalidity defenses are prominent; success depends on prior art analysis.
- Claim construction significantly impacts infringement assessment.
- Patent enforceability hinges on procedural compliance during prosecution due to allegations of inequitable conduct.
Financial and Strategic Considerations
- Horizon’s litigation aims to maintain patent rights for a key controlled-release platform.
- Teva aims to clear the patent barrier for market entry of a competing generic product.
- Settlement negotiations and potential patent challenges could influence market timing.
Conclusion
The case exemplifies ongoing patent enforcement efforts in the pharmaceutical industry, focusing on controlled-release technologies. The outcome will clarify patent scope and validity, influencing licensing strategies and generic market entry.
Key Takeaways
- The dispute hinges on the interpretation of specific claim terms related to tablet composition and structure.
- Validity challenges are central, with prior art referenced to question patent novelty and non-obviousness.
- The litigation’s resolution could impact controlled-release drug markets and generic competition.
FAQs
1. What are the core patent claims in Horizon’s '088 patent?
The patent claims relate to a specific binder used in a layered, controlled-release tablet, emphasizing its structure and manufacturing process.
2. How does Teva defend against patent infringement?
Teva argues its product employs different manufacturing processes and compositions, which do not infringe on the patent claims.
3. What is the significance of the Markman ruling?
It clarifies key claim terms, narrowing or expanding the scope of patent protection, directly affecting infringement and validity analyses.
4. Could invalidity defenses nullify Horizon’s patent rights?
Yes. If Teva proves prior art renders the patent obvious or anticipated, the patent could be invalidated.
5. What are the possible outcomes of this case?
The court may find in favor of Horizon, upholding patent rights and delaying generic sales, or favor Teva, allowing market entry and potentially invalidating the patent.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,657,088.
- Federal Judicial Center. (2022). Patent Litigation Case Management Procedures.
- Court docket 2:20-cv-08188, District of New Jersey.
